Global life science industry outlook report 2021 From Deloitte Consulting

The following is the Global life science industry outlook report 2021 From Deloitte Consulting recommended by recordtrend.com. And this article belongs to the classification: Deloitte Consulting , Life data, research report.

We suggest that the life sciences enterprises in the world should focus on the ecosystem changes brought by COVID-19, and learn from it, and enhance the following seven aspects in the coming year.

Redesign of work, place and labor to meet individual needs

Work is being reshaped and flexibility is more important than ever. In the next year, enterprises should take an in-depth look at the human resources department and its changing new role, covering jobs, workplaces and the whole labor force; And explore ways to let employees keep emotional connection no matter what kind of work style and workplace, and integrate happiness into culture.

Accelerating digital development: new medical places, pharmaceutical enterprises and medical technology enterprises play new roles

With the rapid development of virtual medicine, pharmaceutical enterprises play a greater role in the continuity of medical care. Governments are gradually increasing investment and support for telemedicine and virtual health care services, and relaxing regulatory requirements. During the epidemic period, the drug delivery business increased sharply, and retail pharmacies are constantly providing higher level of medical care services. The competition between medical technology enterprises and consumer technology enterprises is fierce, providing virtual nursing, home nursing and remote monitoring services for consumers.

Establish a new customer-centered business model: the place for consultation with doctors is not limited, and it depends on the customer’s own situation, so communication will be more meaningful

After the epidemic, the medical business model is transforming to digital and virtual communication, and the communication between sales representatives and doctors is turning to the hybrid mode of video call and door-to-door visit. Life science companies need to rethink how to communicate with doctors and how to drive value on demand through digital channels and products.

New cooperation and clinical trials reshape R & D model

Biopharmaceutical Enterprises are adopting various clinical trial innovation strategies to shorten the time, including new trial design and new technologies such as artificial intelligence. Cooperation among governments, research institutions and private enterprises is becoming more intensive. In the future, more clinical trials will adopt the hybrid mode of face-to-face interview and virtual meeting. The progress of data science and analysis technology will promote the significant transformation of drug research and development to transformative methods.

Shorten R & D audit time and think like a regulator

During the period of COVID-19, regulators around the world not only carried out terminal audit, but worked with the industry to carry out telemedicine clinical trials. The government, industry traditional enterprises and emerging technology enterprises will continue to cooperate to invest in innovative technologies that can be used to treat large-scale diseases based on the development model during the epidemic period. In addition, the best way for enterprises to understand the needs of regulators is to carefully study the inspection and process from the perspective of regulators, and analyze the risks and benefits.

Cross border dependence enhances the demand for supply chain visibility and enterprise return

The current epidemic situation highlights the necessity and urgency of redesigning the supply chain. Enterprises should comprehensively evaluate their end-to-end supply chain plans and incorporate strategic, operational and financial leadership to optimize their operations.

Promoting human progress: environmental, social and governance priorities

Measuring ESG (environmental, social and corporate governance) progress is crucial for the life science industry to build trust and enhance social influence. Enterprises that have incorporated ESG strategy, ESG measurement results and high-quality disclosure into their business models are more likely to be in a favorable position after the crisis, seize opportunities and promote long-term value.

If you want to get the full report, you can contact us by leaving us the comment. If you think the information here might be helpful to others, please actively share it. If you want others to see your attitude towards this report, please actively comment and discuss it. Please stay tuned to us, we will keep updating as much as possible to record future development trends.

RecordTrend.com is a website that focuses on future technologies, markets and user trends. We are responsible for collecting the latest research data, authority data, industry research and analysis reports. We are committed to becoming a data and report sharing platform for professionals and decision makers. We look forward to working with you to record the development trends of today’s economy, technology, industrial chain and business model.Welcome to follow, comment and bookmark us, and hope to share the future with you, and look forward to your success with our help.